Tumor mutation burden (TMB) is a measure of the number of mutations per megabase of DNA in the exon coding region of tumor cell DNA. This metric has become an increasingly important biomarker in cancer research and treatment, particularly in the development of immunotherapies. Studies have shown that higher TMB levels represent a greater number of tumor neoantigens in tumor cells that can be recognized by the immune system. Recently, TMB has attracted significant attention in cancer research as it has been shown to have prognostic and predictive value in a variety of cancer types. TMB can be measured using a variety of technologies including whole exome sequencing (WES), targeted sequencing panel and gene expression profiling.
CD Genomics offers a wide range of TMB reference products to help you analyze TMB as a potential tumor biomarker to predict the efficacy of immunotherapy.
TMB is determined by sequencing the DNA of tumor cells and comparing it to DNA from healthy cells from the same patient. The number of mutations in the tumor DNA is then divided by the total size of the DNA sample to calculate TMB. We develop accurate TMB reference products for use in experimental procedures or quality control of the corresponding kits.
Our TMB reference products are derived from cell lines that mimic patient samples.
The production process is specified as follows:
(1) Tumor cells and leukocytes from patient samples are obtained and passaged.
(2) TMB controls in the form of FFPE, gDNA, and ctDNA are mixed in certain proportions.
(3) The TMB controls are sequenced by WES and the TMB values of paired samples are calculated.
(4) Validated by ddPCR to ensure accurate and stable mutation frequency for each batch of generated reference.
Explore Our Tumor Mutation Burden (TMB) Reference Products:
| Cat. No. | Product Name | Brief Description | Inquiry | Basket |
|---|---|---|---|---|
| TMBR001 | CD TMB-1-T gDNA Reference | CD TMB-1-T gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR002 | CD TMB-1-N gDNA Reference | CD TMB-1-N gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR003 | CD TMB-4-T gDNA Reference | CD TMB-4-T gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR004 | CD TMB-4-N gDNA Reference | CD TMB-4-N gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR005 | CD TMB-12-T gDNA Reference | CD TMB-12-T gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR006 | CD TMB-12-N gDNA Reference | CD TMB-12-N gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR007 | CD TMB-6-T gDNA Reference | CD TMB-6-T gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR008 | CD TMB-6-N gDNA Reference | CD TMB-6-N gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR009 | CD TMB-13-T gDNA Reference | CD TMB-13-T gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. | ||
| TMBR010 | CD TMB-13-N gDNA Reference | CD TMB-13-N gDNA Reference is obtained from tumor cells and leukocytes from the same patient sample. The cells are cultured and mixed in a certain ratio to produce FFPE, gDNA, and ctDNA controls. The controls are subjected to WES sequencing, calculation of paired sample TMB values, and ddPCR validation. Also, clinical samples with different tumor contents can be simulated by mixing tumor and normal cells. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
